Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2017 06:00 ET | Source: CytoDyn Inc.

CytoDyn to Present at the 7th Annual LD Micro Invitational on June 6

VANCOUVER, Washington, June 02, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
June 01, 2017 06:00 ET | Source: CytoDyn Inc.

CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017

VANCOUVER, Washington, June 01, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human...
May 17, 2017 06:00 ET | Source: CytoDyn Inc.

CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease

VANCOUVER, Washington, May 17, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus...
April 17, 2017 06:00 ET | Source: CytoDyn Inc.

Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA

VANCOUVER, Washington, April 17, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human...
April 13, 2017 16:10 ET | Source: CytoDyn Inc.

Reminder: CytoDyn to Hold Investment Community Conference Call April 18, 2017

VANCOUVER, Washington, April 13, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human...
April 11, 2017 06:00 ET | Source: CytoDyn Inc.

CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors

VANCOUVER, Washington, April 11, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human...
April 06, 2017 16:13 ET | Source: CytoDyn Inc.

CytoDyn Announces Investment Community Conference Call for April 18, 2017

VANCOUVER, Washington, April 06, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human...
February 15, 2017 19:00 ET | Source: CytoDyn Inc.

Data Presented at CROI Show CytoDyn’s Pro 140 as a Single Agent Provided Maximal Virologic Suppression in HIV Patients for Nearly Two Years

VANCOUVER, Washington, Feb. 15, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
February 14, 2017 06:30 ET | Source: CytoDyn Inc.

Two-Year Update From CytoDyn’s PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017

VANCOUVER, Washington, Feb. 14, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
January 30, 2017 06:30 ET | Source: CytoDyn Inc.

CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman

VANCOUVER, Washington, Jan. 30, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...